期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌中EML4-ALK融合基因的生物学特性及其治疗 被引量：6

Biological characteristics and therapeutic application of EML4-ALK fusion gene in non-small cell lung cancer
原文传递
导出
摘要 在非小细胞肺癌(non-small cell lung cancer,NSCLC)中已发现棘皮动物微管相关蛋白样4(echinoderm microtubule-associated protein-like4,EML4)和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)的融合基因。在不吸烟的NSCLC患者中大多可检测出EML4-ALK,其具有独特的病理学特征。EML4-ALK在体内外均有致癌性。ALK抑制剂(crizotinib)在EML4-ALK阳性的NSCLC患者中已取得较好的治疗效果。本综述重点阐述NSCLC中EML4-ALK的生物学特性、临床特征和治疗。 The fusion gene between echinoderm EMI4 （microtubule-associated protein-like 4） and AI_K （anaplastic lymphoma kinase） has been identified in non-small cell lung cancer （NSCLC）. EML4-ALK is most commonly detected in never smokers with NSCLC and has unique pathologic features. EML4- ALK is oncogenic both in vitro and in vitro. ALK inhibitor （crizotinib） has demonstrated a remarkable clinical efficacy in EML4-ALK-positive NSCLC patients. This review emphasizes the biological and clinical characteristics and the therapeutic application of EML4-ALK in NSCLC.
作者 杨彦卓 潘乐康 安广宇
机构地区 天津医科大学附属肿瘤医院高级病房天津市肿瘤防治重点实验室 天津医科大学附属肿瘤医院乳腺癌防治研究中心天津市肿瘤防治重点实验室 首都医科大学附属北京世纪坛医院肿瘤科
出处 《肿瘤》 CAS CSCD 北大核心 2012年第6期466-470,共5页 Tumor
基金 国家自然科学基金面上项目(编号:81070415)
关键词 癌 非小细胞肺 肿瘤治疗方案 融合基因 EML4-ALK Carcinoma, non-small cell lung Antineoplasms protocols Fusion gene, EMI4-ALK
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1INAMURA K, TAKEUCHI K, TOGASHI Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset[J]. Mod Pathol, 2009, 22(4): 508-515.
  • 2SODA M, CHOI Y L, ENOMOTO M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
  • 3SHIOTA M, FUJIMOTO J, SEMBA T, et al. Hyperphosphorylation of a novel 80 kDa protein- tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 [J]. Oncogene, 1994, 9(6): 1567-1574.
  • 4MORRIS S W, NAEVE C, MATHEW P, et al. AI_K, the chromosome 2 gene focus altered by the t(2; 5)in non- Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)[J]. Oncogene, 1997, 14(18): 2175-2188.
  • 5夏曙,于世英.PI3K/Akt信号转导通路在恶性肿瘤中的研究进展[J].肿瘤,2006,26(6):576-578. 被引量：28
  • 6KWAK E L, CAMIDGE D R, CLARK J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066[J].J Clin Oncol, 2009, 27(15s): 3509.
  • 7EICHENMULLER B, EVERLEY P, PALANGE J, et al. The human EMAP-like protein-70 (ELP70) is a microtubule destabilize that localizes to the mitotic apparatus[J]. J Biol Chem, 2002, 277(2): 1301-1309.
  • 8ZHANG X, ZHANG S, YANG X, et al. Fusion of EMI4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression[J]. Mol Cancer, 2010, 9: 188.
  • 9SHAW A T, YEAP B Y, MINO-KENUDSON M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J].J C/in Oncol, 2009 27(26): 4247-4253.

二级参考文献21

  • 1SHTIVELMAN E,SUSSMAN J ,STOKOE D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle[J]. Curr Biol , 2002,12( 11 ) : 919-924.
  • 2MAYO L D, DONNER D B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of mdm2 from the cytoplasm to the nucleus[J]. Proc Natl Acad Sci USA, 2001,98(20) : 11598-115603.
  • 3HENSHALL DC,ARAKI T,SCHINKLER CK,et al. Activation of bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death[J]. J Neurosci ,2002,22(19):8458-8465.
  • 4XIN M, DENG X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation[J]. J Biol Chem ,2005,280(11):10781-10789.
  • 5BARTLING B, TOSTLEBE H, DARMER D, et al. Shear stress-dependent expression of apoptosis-regulating genes in endothelial cells[J]. Biochem Biophys Res Commun , 2000,278(3):740-746.
  • 6LI N,BANIN S, OUYANG H, et al. ATM is required for Ikappa B kinase (IKKk) activation in response to DNA double strand breaks[J]. J Biol Chem ,2001,276(12):8898-8903.
  • 7GIBSON E M, HENSON E S, HANEY N, et al . Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release[J]. Cancer Res , 2002,62(2):488-496.
  • 8COFFEY JC,WANG J H,SMITH M J, et al . Phosphoinositide 3 kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis-novel role for an old enemy[J]. J Biol Chem ,2005,280(22):20968-20977.
  • 9HILL K,WELTI S, YU J, et al . Specific requirement for the p85-p110 alpha phosphatidylinositol 3-kinase during epidermal growth factor-stimulated actin nucleation in breast cancer cells[J]. J Biol Chem ,2000,275(6):3741-3744.
  • 10MAIER D,JONES G,LI X, et al . The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells[J]. Cancer Res , 1999,59(21) :5479-5482.

共引文献27

同被引文献87

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量：126
  • 2DOUILLARD J v, SHEPHERD F A, HIRSH V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small- cell lung cancer: date from the randomized phase III IN TERES T trial[J].J Clin Oncol, 2010, 28(S):744-752.
  • 3CAPPUZZO F, CIULEANU T, STELMAKH L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studv[J]. Lancet Oneal, 2010,11(6):521-529.
  • 4RHO J K, CHOI Y J, JEON B S, et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation[J]. Mal Cancer Ther, 2010, 9(12):3233-3243.
  • 5MA C, WEI S, SONG Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports[J]. Tharacic Dis, 2011, 3(1): 10-18.
  • 6EBERHARD D A, JOHNSON B Eo AMLER L C, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol, 2005, 23(25): 5900-5909.
  • 7JACKMAN D, PAO W, RIELY G J, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].J Clin Oneal, 2010,28(2):357-360.
  • 8LI D, AMBROGIO L, SHIMAMURA T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models[J], Oncogene, 2008, 27(34):4702-4711.
  • 9REGLES L, GONG Y, SHEN R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of ECFR mutant lung cancer[J].J Clin Invest, 2009, 119(10):3000-3010.
  • 10MOK T S, WU Y L. THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361 :947-957.

引证文献6

二级引证文献41

肿瘤
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部